[1] F.G. Giancotti, E. Ruoslahti, Integrin signaling., Science. 285 (1999) 1028–32.
[2] R.O. Hynes, Integrins: bidirectional, allosteric signaling machines., Cell. 110 (2002) 673–87.
[3] M. Cheah, M.R. Andrews, Integrin Activation: Implications for Axon Regeneration., Cells. 7 (2018).
[4] F. Ye, C. Kim, M.H. Ginsberg, Reconstruction of integrin activation, Blood. 119 (2012) 26–33.
[5] G.E. Davis, K.J. Bayless, M.J. Davis, G.A. Meininger, Regulation of tissue injury responses by the exposure of matricryptic sites within extracellular matrix molecules., Am. J. Pathol. 156 (2000) 1489–98.
[6] J.W. Lee, R.L. Juliano, alpha5beta1 integrin protects intestinal epithelial cells from apoptosis through a phosphatidylinositol 3-kinase and protein kinase B-dependent pathway., Mol. Biol. Cell. 11 (2000) 1973–87.
[7] Z. Zhang, K. Vuori, J.C. Reed, E. Ruoslahti, The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression., Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 6161–5.
[8] A. Morla, Z. Zhang, E. Ruoslahti, Superfibronectin is a functionally distinct form of fibronectin., Nature. 367 (1994) 193–6.
[9] C. Zhong, M. Chrzanowska-Wodnicka, J. Brown, A. Shaub, A.M. Belkin, K. Burridge, Rho-mediated contractility exposes a cryptic site in fibronectin and induces fibronectin matrix assembly., J. Cell Biol. 141 (1998) 539–51.
[10] H.P. Erickson, Stretching fibronectin, J. Muscle Res. Cell Motil. 23 (2002) 575–580.
[11] A. V Shinde, C. Bystroff, C. Wang, M.G. Vogelezang, P.A. Vincent, R.O. Hynes, L. Van De Water, Identification of the peptide sequences within the EIIIA (EDA)segment of fibronectin that mediate integrin alpha9beta1-dependent cellular activities.,J. Biol. Chem. 283 (2008) 2858–70.
[12] C. Mas-Moruno, F. Rechenmacher, H. Kessler, Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation., Anticancer. Agents Med. Chem. 10 (2010) 753–68.
[13] F. Fukai, H. Takahashi, Y. Habu, N. Kubushiro, T. Katayama, Fibronectin harbors anticell adhesive activity., Biochem. Biophys. Res. Commun. 220 (1996) 394–8.
[14] K. Watanabe, H. Takahashi, Y. Habu, N. Kamiya-Kubushiro, S. Kamiya, H. Nakamura, H. Yajima, T. Ishii, T. Katayama, K. Miyazaki, F. Fukai, Interaction with heparin and matrix metalloproteinase 2 cleavage expose a cryptic anti-adhesive site of fibronectin., Biochemistry. 39 (2000) 7138–44.
[15] Y. Saito, T. Owaki, F. Fukai, Cell Regulation through Membrane Rafts/Caveolae, in: Electr. Phenom. Interfaces Biointerfaces, John Wiley & Sons, Inc., Hoboken, NJ, USA, 2012: pp. 767–781.
[16] R. Kato, T. Ishikawa, S. Kamiya, F. Oguma, M. Ueki, S. Goto, H. Nakamura, T. Katayama, F. Fukai, A new type of antimetastatic peptide derived from fibronectin., Clin. Cancer Res. 8 (2002) 2455–62.
[17] T. Matsunaga, F. Fukai, S. Miura, Y. Nakane, T. Owaki, H. Kodama, M. Tanaka, T. Nagaya, R. Takimoto, T. Takayama, Y. Niitsu, Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion- mediated drug resistance of acute myelogenous leukemia., Leukemia. 22 (2008) 353– 60.
[18] F. Fukai, M. Mashimo, K. Akiyama, T. Goto, S. Tanuma, T. Katayama, Modulation of apoptotic cell death by extracellular matrix proteins and a fibronectin-derived antiadhesive peptide., Exp. Cell Res. 242 (1998) 92–9.
[19] S. Kamiya, R. Kato, M. Wakabayashi, T. Tohyama, I. Enami, M. Ueki, H. Yajima, T. Ishii, H. Nakamura, T. Katayama, J. Takagi, F. Fukai, Fibronectin peptides derived from two distinct regions stimulate adipocyte differentiation by preventing fibronectin matrix assembly., Biochemistry. 41 (2002) 3270–7.
[20] R. Kato, S. Kamiya, M. Ueki, H. Yajima, T. Ishii, H. Nakamura, T. Katayama, F. Fukai, The fibronectin-derived antiadhesive peptides suppress the myofibroblastic conversion of rat hepatic stellate cells., Exp. Cell Res. 265 (2001) 54–63.
[21] S. Miura, S. Kamiya, Y. Saito, S. Wada, R. Hayashi, J. Taira, H. Kodama, H. Yajima,M. Ueki, F. Fukai, Antiadhesive Sites Present in the Fibronectin Type III-Like Repeats of Human Plasma Fibronectin, Biol. Pharm. Bull. 30 (2007) 891–897.
[22] J.E. Meredith, B. Fazeli, M.A. Schwartz, The extracellular matrix as a cell survival factor., Mol. Biol. Cell. 4 (1993) 953–61.
[23] S.M. Frisch, H. Francis, Disruption of epithelial cell-matrix interactions induces apoptosis., J. Cell Biol. 124 (1994) 619–26.
[24] Y. Gavrieli, Y. Sherman, S.A. Ben-Sasson, Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation., J. Cell Biol. 119 (1992) 493– 501.
[25] G. Gabbiani, The myofibroblast in wound healing and fibrocontractive diseases., J. Pathol. 200 (2003) 500–3.
[26] D.G. Stupack, D.A. Cheresh, Get a ligand, get a life: integrins, signaling and cell survival., J. Cell Sci. 115 (2002) 3729–38.
[27] E. Ruoslahti, Fibronectin and its integrin receptors in cancer., Adv. Cancer Res. 76 (1999) 1–20.
[28] S. Bialik, V.L. Cryns, A. Drincic, S. Miyata, A.L. Wollowick, A. Srinivasan, R.N. Kitsis, The mitochondrial apoptotic pathway is activated by serum and glucosedeprivation in cardiac myocytes., Circ. Res. 85 (1999) 403–14.
[29] P. Carmeliet, R.K. Jain, Angiogenesis in cancer and other diseases., Nature. 407 (2000) 249–57.
[30] N. Sonenberg, J.W.B. Hershey, M. Mathews, Translational control of gene expression, Cold Spring Harbor Laboratory Press, 2000.
[31] S. EJIRI, Moonlighting Functions of Polypeptide Elongation Factor 1: From Actin Bundling to Zinc Finger Protein R1-Associated Nuclear Localization, Biosci. Biotechnol. Biochem. 66 (2002) 1–21.
[32] S. Nishiumi, H. Ashida, Rapid preparation of a plasma membrane fraction from adipocytes and muscle cells: application to detection of translocated glucose transporter 4 on the plasma membrane., Biosci. Biotechnol. Biochem. 71 (2007) 2343–6.
[33] Y. Saito, H. Imazeki, S. Miura, T. Yoshimura, H. Okutsu, Y. Harada, T. Ohwaki, O. Nagao, S. Kamiya, R. Hayashi, H. Kodama, H. Handa, T. Yoshida, F. Fukai, A peptide derived from tenascin-C induces beta1 integrin activation through syndecan-4., J. Biol. Chem. 282 (2007) 34929–37.
[34] G. Bazzoni, D.T. Shih, C.A. Buck, M.E. Hemler, Monoclonal antibody 9EG7 defines a novel beta 1 integrin epitope induced by soluble ligand and manganese, but inhibited by calcium., J. Biol. Chem. 270 (1995) 25570–7.
[35] K. Itagaki, T. Naito, R. Iwakiri, M. Haga, S. Miura, Y. Saito, T. Owaki, S. Kamiya, T. Iyoda, H. Yajima, S. Iwashita, S. Ejiri, F. Fukai, Eukaryotic translation elongation factor 1A induces anoikis by triggering cell detachment., J. Biol. Chem. 287 (2012) 16037–46.
[36] A. Signorell, J. Jelk, M. Rauch, P. Bütikofer, Phosphatidylethanolamine is the precursor of the ethanolamine phosphoglycerol moiety bound to eukaryotic elongationfactor 1A., J. Biol. Chem. 283 (2008) 20320–9.
[37] E. Greganova, P. Bütikofer, Ethanolamine phosphoglycerol attachment to eEF1A is not essential for normal growth of Trypanosoma brucei., Sci. Rep. 2 (2012) 254.
[38] I. Tanida, T. Ueno, E. Kominami, LC3 and Autophagy., Methods Mol. Biol. 445 (2008) 77–88.
[39] F. Gibellini, T.K. Smith, The Kennedy pathway-De novo synthesis of phosphatidylethanolamine and phosphatidylcholine, IUBMB Life. 62 (2010) n/a-n/a.
[40] J.-B. Michel, Anoikis in the cardiovascular system: known and unknown extracellular mediators., Arterioscler. Thromb. Vasc. Biol. 23 (2003) 2146–54.
[41] F. Bonavita, C. Stefanelli, E. Giordano, M. Columbaro, A. Facchini, F. Bonafè, C.M. Caldarera, C. Guarnieri, H9c2 cardiac myoblasts undergo apoptosis in a model of ischemia consisting of serum deprivation and hypoxia: inhibition by PMA., FEBS Lett. 536 (2003) 85–91.
[42] G. Rennebeck, M. Martelli, N. Kyprianou, Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis?, Cancer Res. 65 (2005) 11230–5.
[43] M.F. Hanzal-Bayer, J.F. Hancock, Lipid rafts and membrane traffic, FEBS Lett. 581 (2007) 2098–2104.
[44] A. Hosomi, K. Iida, T. Cho, H. Iida, M. Kaneko, T. Suzuki, The ER-associated protease Ste24 prevents N-terminal signal peptide-independent translocation into the endoplasmic reticulum in Saccharomyces cerevisiae, J. Biol. Chem. 295 (2020) 10406–10419.
[45] S. Ohkubo, N. Nakahata, [Role of lipid rafts in trimeric G protein-mediated signal transduction]., Yakugaku Zasshi. 127 (2007) 27–40.
[46] P. Gerold, V. Eckert, R.T. Schwarz, T. Yamada, GPI-Anchors: An Overview., TrendsGlycosci. Glycotechnol. 8 (1996) 265–277.
[47] Y. Wei, C.-H. Tang, Y. Kim, L. Robillard, F. Zhang, M.C. Kugler, H.A. Chapman, Urokinase receptors are required for alpha 5 beta 1 integrin-mediated signaling in tumor cells., J. Biol. Chem. 282 (2007) 3929–39.
[48] G.R. Jacobson, J.P. Rosenbusch, Abundance and membrane association of elongation factor Tu in E. coli., Nature. 261 (1976) 23–6.
[49] S.F. Dallo, T.R. Kannan, M.W. Blaylock, J.B. Baseman, Elongation factor Tu and E1 beta subunit of pyruvate dehydrogenase complex act as fibronectin binding proteins in Mycoplasma pneumoniae., Mol. Microbiol. 46 (2002) 1041–51.
[50] D. Granato, G.E. Bergonzelli, R.D. Pridmore, L. Marvin, M. Rouvet, I.E. Corthésy- Theulaz, Cell surface-associated elongation factor Tu mediates the attachment of Lactobacillus johnsonii NCC533 (La1) to human intestinal cells and mucins., Infect. Immun. 72 (2004) 2160–9.
[51] A. Kunert, J. Losse, C. Gruszin, M. Hühn, K. Kaendler, S. Mikkat, D. Volke, R. Hoffmann, T.S. Jokiranta, H. Seeberger, U. Moellmann, J. Hellwage, P.F. Zipfel, Immune evasion of the human pathogen Pseudomonas aeruginosa: elongation factor Tuf is a factor H and plasminogen binding protein., J. Immunol. 179 (2007) 2979–88.
[52] S. Balasubramanian, T.R. Kannan, J.B. Baseman, The surface-exposed carboxyl region of Mycoplasma pneumoniae elongation factor Tu interacts with fibronectin., Infect. Immun. 76 (2008) 3116–23.
[53] J.P. Nataro, P.S. Cohen, H.L.T. Mobley, J.N. Weiser, eds., Colonization of Mucosal Surfaces, ASM Press, Washington, DC, USA, 2005.
[54] M.A. Mulvey, J.D. Schilling, J.J. Martinez, S.J. Hultgren, Bad bugs and beleaguered bladders: interplay between uropathogenic Escherichia coli and innate host defenses., Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 8829–35.
[55] L.J. Cliffe, N.E. Humphreys, T.E. Lane, C.S. Potten, C. Booth, R.K. Grencis, Accelerated intestinal epithelial cell turnover: a new mechanism of parasite expulsion., Science. 308 (2005) 1463–5.
[56] M. Kim, M. Ogawa, Y. Fujita, Y. Yoshikawa, T. Nagai, T. Koyama, S. Nagai, A. Lange, R. Fässler, C. Sasakawa, Bacteria hijack integrin-linked kinase to stabilize focal adhesions and block cell detachment., Nature. 459 (2009) 578–82.
[57] W.G. Jiang, A.J. Sanders, M. Katoh, H. Ungefroren, F. Gieseler, M. Prince, S.K. Thompson, M. Zollo, D. Spano, P. Dhawan, D. Sliva, P.R. Subbarayan, M. Sarkar, K. Honoki, H. Fujii, A.G. Georgakilas, A. Amedei, E. Niccolai, A. Amin, S.S. Ashraf, L. Ye, W.G. Helferich, X. Yang, C.S. Boosani, G. Guha, M.R. Ciriolo, K. Aquilano, S. Chen, A.S. Azmi, W.N. Keith, A. Bilsland, D. Bhakta, D. Halicka, S. Nowsheen, F. Pantano, D. Santini, Tissue invasion and metastasis: Molecular, biological and clinical perspectives, Semin. Cancer Biol. 35 (2015) S244–S275.
[58] L.A. Liotta, Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture., Cancer Res. 46 (1986) 1–7.
[59] P. Friedl, K. Wolf, Tumour-cell invasion and migration: diversity and escape mechanisms, Nat. Rev. Cancer. 3 (2003) 362–374.
[60] H. Hamidi, J. Ivaska, Every step of the way: integrins in cancer progression and metastasis, Nat. Rev. Cancer. 18 (2018) 533–548.
[61] R.E. Vandenbroucke, C. Libert, Is there new hope for therapeutic matrix metalloproteinase inhibition?, Nat. Rev. Drug Discov. 13 (2014) 904–927.
[62] E.H.J. Danen, Integrin Signaling as a Cancer Drug Target, ISRN Cell Biol. 2013 (2013) 1–14.
[63] C.T. Mierke, B. Frey, M. Fellner, M. Herrmann, B. Fabry, S.M. Watt, D.L. Simmons,Integrin α5β1 facilitates cancer cell invasion through enhanced contractile forces., J.Cell Sci. 124 (2011) 369–83.
[64] J.D. Hood, D.A. Cheresh, Role of integrins in cell invasion and migration, Nat. Rev.Cancer. 2 (2002) 91–100.
[65] J.S. Desgrosellier, D.A. Cheresh, Integrins in cancer: biological implications and therapeutic opportunities., Nat. Rev. Cancer. 10 (2010) 9–22.
[66] T. Sugimori, D.L. Griffith, M.A. Arnaout, Emerging paradigms of integrin ligand binding and activation., Kidney Int. 51 (1997) 1454–62.
[67] D.A. Lauffenburger, A.F. Horwitz, Cell migration: a physically integrated molecular process., Cell. 84 (1996) 359–69.
[68] W.T. Chen, Mechanism of retraction of the trailing edge during fibroblast movement.,J. Cell Biol. 90 (1981) 187–200.
[69] R. Ananthakrishnan, A. Ehrlicher, The Forces Behind Cell Movement, Int. J. Biol. Sci. (2007) 303–317.
[70] K. Kessenbrock, V. Plaks, Z. Werb, Matrix Metalloproteinases: Regulators of the Tumor Microenvironment, Cell. 141 (2010) 52–67.
[71] K. Nabeshima, T. Inoue, Y. Shimao, T. Sameshima, Matrix metalloproteinases in tumor invasion: role for cell migration., Pathol. Int. 52 (2002) 255–64.
[72] E.A. Seftor, P.S. Meltzer, D.A. Kirschmann, J. Pe’er, A.J. Maniotis, J.M. Trent, R. Folberg, M.J.C. Hendrix, Molecular determinants of human uveal melanoma invasion and metastasis., Clin. Exp. Metastasis. 19 (2002) 233–46.
[73] R. Folberg, S.S. Kadkol, S. Frenkel, K. Valyi-Nagy, M.J. Jager, J. Pe’er, A.J. Maniotis, Authenticating cell lines in ophthalmic research laboratories., Invest. Ophthalmol. Vis. Sci. 49 (2008) 4697–701.
[74] J.A. Greenwood, J.E. Murphy-Ullrich, Signaling of de-adhesion in cellular regulation and motility, Microsc. Res. Tech. 43 (1998) 420–432.
[75] J.E. Murphy-Ullrich, The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state?, J. Clin. Invest. 107 (2001) 785–90.
[76] S.J. Franco, A. Huttenlocher, Regulating cell migration: calpains make the cut, J. Cell Sci. 118 (2005) 3829–3838.
[77] F.J. Sulzmaier, J.W. Ramos, RSK isoforms in cancer cell invasion and metastasis., Cancer Res. 73 (2013) 6099–105.
[78] P.L. Triozzi, W. Aldrich, A. Singh, Effects of Interleukin-1 Receptor Antagonist on Tumor Stroma in Experimental Uveal Melanoma, Investig. Opthalmology Vis. Sci. 52 (2011) 5529.
[79] Exposure of the cryptic de-adhesive site FNIII14 in fibronectin molecule and its binding to membrane-type eEF1A induce migration and invasion of cancer cells via β1-integrin inactivation - PubMed, (n.d.).
[80] E. Ziegler, M.-T. Hansen, M. Haase, G. Emons, C. Gründker, Generation of MCF-7 cells with aggressive metastatic potential in vitro and in vivo., Breast Cancer Res. Treat. 148 (2014) 269–77.
[81] M.A. Bausero, A. Bharti, D.T. Page, K.D. Perez, J.W.-L. Eng, S.L. Ordonez, E.E. Asea, C. Jantschitsch, I. Kindas-Muegge, D. Ciocca, A. Asea, Silencing the hsp25 gene eliminates migration capability of the highly metastatic murine 4T1 breast adenocarcinoma cell., Tumour Biol. 27 (2006) 17–26.
[82] H. Nakanishi, Y. Kodera, M. Tatematsu, Molecular method to quantitatively detect micrometastases and its clinical significance in gastrointestinal malignancies., Adv. Clin. Chem. 38 (2004) 87–110.
[83] T. Giese, M. Engstner, U. Mansmann, W. Hartschuh, B. Arden, Quantification of Melanoma Micrometastases in Sentinel Lymph Nodes Using Real-Time RT-PCR, J. Invest. Dermatol. 124 (2005) 633–637.
[84] M. Kyutoku, Y. Taniyama, N. Katsuragi, H. Shimizu, Y. Kunugiza, K. Iekushi, N. Koibuchi, F. Sanada, Y. Oshita, R. Morishita, Role of periostin in cancer progression and metastasis: inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model., Int. J. Mol. Med. 28 (2011) 181–6.
[85] Y. Zhao, Y. Wang, A. Sarkar, X. Wang, Keratocytes Generate High Integrin Tension at the Trailing Edge to Mediate Rear De-adhesion during Rapid Cell Migration., IScience. 9 (2018) 502–512.
[86] J.E. Gawecka, S.S. Young-Robbins, F.J. Sulzmaier, M.J. Caliva, M.M. Heikkilä, M.L. Matter, J.W. Ramos, RSK2 protein suppresses integrin activation and fibronectin matrix assembly and promotes cell migration., J. Biol. Chem. 287 (2012) 43424–37.
[87] S.M. Knudsen, J. Frydenberg, B.F. Clark, H. Leffers, Tissue-dependent variation in the expression of elongation factor-1 alpha isoforms: isolation and characterisation of a cDNA encoding a novel variant of human elongation-factor 1 alpha., Eur. J. Biochem. 215 (1993) 549–54.
[88] V.A.L. Tomlinson, H.J. Newbery, N.R. Wray, J. Jackson, A. Larionov, W.R. Miller,J.M. Dixon, C.M. Abbott, Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours., BMC Cancer. 5 (2005) 113.
[89] M.-H. Lee, Y.-J. Surh, eEF1A2 as a Putative Oncogene, Ann. N. Y. Acad. Sci. 1171 (2009) 87–93.
[90] N. Anand, S. Murthy, G. Amann, M. Wernick, L.A. Porter, I.H. Cukier, C. Collins,J.W. Gray, J. Diebold, D.J. Demetrick, J.M. Lee, Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer, Nat. Genet. 31 (2002) 301–305.
[91] S. Yang, M. Lu, Y. Chen, D. Meng, R. Sun, D. Yun, Z. Zhao, D. Lu, Y. Li, Overexpression of eukaryotic elongation factor 1 alpha-2 is associated with poorerprognosis in patients with gastric cancer., J. Cancer Res. Clin. Oncol. 141 (2015) 1265–75.
[92] S. Sharma, J. Tammela, X. Wang, H. Arnouk, D. Driscoll, P. Mhawech-Fauceglia, S. Lele, A.L. Kazim, K. Odunsi, Characterization of a putative ovarian oncogene, elongation factor 1alpha, isolated by panning a synthetic phage display single-chain variable fragment library with cultured human ovarian cancer cells., Clin. Cancer Res. 13 (2007) 5889–96.
[93] M. Kawamura, C. Endo, A. Sakurada, F. Hoshi, H. Notsuda, T. Kondo, The prognostic significance of eukaryotic elongation factor 1 alpha-2 in non-small cell lung cancer., Anticancer Res. 34 (2014) 651–8.
論文の公開元へ
